Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Prostate cancer (PCa) is androgen-dependent, with androgen deprivation therapy (ADT) as a primary treatment.
• Chronic ADT leads to castration-resistant prostate cancer (CRPC), where tumors adapt and resist treatment.
• CRPC cells remain dependent on androgen receptor (AR) signaling, responding initially to newer AR signaling inhibitors (ARSis).

Purpose of the Study:

• To review strategies and drugs that resensitize CRPC cells to previously used treatments.
• To explore the potential of "hinge" therapies in overcoming acquired resistance to antiandrogenic agents.
• To identify novel therapeutic approaches for nonresponsive advanced prostate cancer.

Main Methods:

• Review of existing literature on CRPC treatment resistance mechanisms.
• Analysis of drugs and strategies aimed at resensitizing tumors to ARSis.
• Examination of "hinge" treatments and their synergistic effects.

Main Results:

• Several drugs and strategies, including bipolar androgen therapy (BAT), indomethacin, niclosamide, lapatinib, panobinostat, clomipramine, metformin, and antisense oligonucleotides, show promise.
• These agents demonstrate an inhibitory effect on PCa and the ability to overcome acquired resistance to antiandrogenic agents.
• Resensitization of tumor cells to previously used ARSis is a key outcome.

Conclusions:

• Targeting AR signaling persistence and reactivation in CRPC is a viable therapeutic strategy.
• "Hinge" treatments offer a promising approach to overcome acquired resistance in advanced prostate cancer.
• Combination therapies and resensitization strategies are crucial for improving outcomes in CRPC.